Treating Relapsed Acute Lymphoblastic Leukemia in Pediatric Patients
Article Sidebar
Main Article Content
Abstract
An editorial commentary on the study by Makiya et al., "Treatment of Relapse in Pediatric Patients with Acute Lymphoblastic Leukemia in Argentina: Results from a Clinical Trial and a Prospective Cohort," the situation of acute leukemias in pediatrics and their relapses in Argentina and their treatment options are mentioned and contextualized.
Downloads
Article Details
Section
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
How to Cite
References
Moreno F, Chaplin A. Registro oncopediátrico argentino [Internet]. 7a ed. Ciudad Autónoma de Buenos Aires: Instituto Nacional del Cáncer; 2021 [citado 2024 may 5]. Disponible en: https://bancos.salud.gob.ar/sites/default/files/2022-07/07-22-Registro-oncopedi%C3%A1trico-argentino.pdf.
Guitter M, Alfaro E, Rossi J, et al. Resultados del tratamiento de leucemias linfoblásticas agudas recaídas en pediatría: experiencia en una institución. Hematología. 2010;14(1): 4-10.
Hunger SP, Raetz EA. How I treat relapsed acute lymphoblastic leukemia in the pediatric population. Blood. 2020;136(16):1803-1812. https://doi.org/10.1182/blood.2019004043. DOI: https://doi.org/10.1182/blood.2019004043
Geyer MB, Tallman MS. Digging deeper in relapsed acute lymphoblastic leukemia: impact of MRD status on outcome in second remission. Leuk Lymphoma. 2018;59(2):269-271. https://doi.org/10.1080/10428194.2017.1355971. DOI: https://doi.org/10.1080/10428194.2017.1355971
Eckert C, Henze G, Seeger K, et al. Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk group. J Clin Oncol. 2013;31(21):2736-2742. https://doi.org/10.1200/JCO.2012.48.5680. DOI: https://doi.org/10.1200/JCO.2012.48.5680
Brown PA, Ji L, Xu X, et al. A randomized phase 3 trial of blinatumomab vs. chemotherapy as post-reinduction therapy in high and intermediate risk (HR/IR) first relapse of B-acute lymphoblastic leukemia (B-ALL) in children and adolescents/young adults (AYAs) demonstrates superior efficacy and tolerability of blinatumomab: a report from Children Oncology Group Study AALL1331 [abstract]. Blood. 2019;134(Suppl 2):LBA-1. https://doi.org/10.1182/blood-2019-132435. DOI: https://doi.org/10.1182/blood-2019-132435
Harned TM, Gaynon P. Relapsed acute lymphoblastic leukemia: current status and future opportunities. Curr Oncol Rep. 2008;10(6):453-458. https://doi.org/10.1007/s11912-008-0070-3. DOI: https://doi.org/10.1007/s11912-008-0070-3
Makiya ML, Dibar E, Altuna D, et al. Tratamiento de la recaída de pacientes pediátricos con leucemia linfoblástica aguda en la Argentina: resultados de un ensayo clínico y una cohorte prospectiva. Rev Hosp Ital B.Aires. 2024;44(1):e0000256. https://doi.org/10.51987/revhospitalbaires.v44i1.256. DOI: https://doi.org/10.51987/revhospitalbaires.v44i1.256
Oskarsson T, Söderhäll S, Arvidson J, et al. Treatment-related mortality in relapsed childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2018;65(4). https://doi.org/10.1002/pbc.26909. DOI: https://doi.org/10.1002/pbc.26909
Harned TM, Gaynon PS. Treating refractory leukemias in childhood, role of clofarabine. Ther Clin Risk Manag. 2008;4(2):327-336. https://doi.org/10.2147/tcrm.s2941. DOI: https://doi.org/10.2147/TCRM.S2941
Kantarjian H, Stein A, Gökbuget N, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376(9):836-847. https://doi.org/10.1056/NEJMoa1609783. DOI: https://doi.org/10.1056/NEJMoa1609783
Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study. Cancer. 2019;125(14):2474-2487. https://doi.org/10.1002/cncr.32116. DOI: https://doi.org/10.1002/cncr.32116
Whitlock JA, Malvar J, Dalla-Pozza L, et al. Nelarabine, etoposide, and cyclophosphamide in relapsed pediatric T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma (study T2008-002 NECTAR). Pediatr Blood Cancer. 2022;69(11):e29901. https://doi.org/10.1002/pbc.29901. DOI: https://doi.org/10.1002/pbc.29901
Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11(4):69. https://doi.org/10.1038/s41408-021-00459-7. DOI: https://doi.org/10.1038/s41408-021-00459-7